Clinical trialsCompany release
NeOnc says NEO100 met Phase 2a endpoint in recurrent IDH1-mutant glioma, but criteria diverge
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Tue 17 Nov 2026
A corporate deck reports 48.9% six-month PFS by RANO 2.0 in 24 patients, yet the protocol-specified RANO criteria gave 25.8%, with an unlocked database.
NeOnc Technologies (NASDAQ: NTHI) has reported results from a Phase 2a study of intranasal NEO100, an ultra-pure form of perillyl alcohol, in recurrent IDH1-mutant grade III–IV glioma. The data appear in a corporate presentation rather than a full publication or regulatory document, and the company says the study met its primary endpoint.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): Neonc Technologies Holdings, Inc. ↗
Article written by VigiEye from the official source (Neonc Technologies Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.
More Clinical trials
All →
Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports
🇨🇦 Health Canada · Wed 18 Nov 2026
Health Canada: Raz Design recalls shower commode chairs over seats that can break
🇨🇦 Health Canada · Wed 18 Nov 2026
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
🇺🇸 Summit Therapeutics Inc. (SMMT) · Wed 18 Nov 2026
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
🇺🇸 Neonc Technologies Holdings, Inc. (NTHI) · Wed 18 Nov 2026
Lantern Pharma opens first TNBC trial site, starts HARMONIC Part 2 in Taiwan; CEO resigns
🇺🇸 Lantern Pharma Inc. (LTRN) · Wed 18 Nov 2026
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
Optimi Health Corp. (OPTH) · Wed 18 Nov 2026